|
AU5727998A
(en)
*
|
1996-12-31 |
1998-07-31 |
Salk Institute For Biological Studies, The |
Treatment of liposarcomas using a combination of thiazolidinediones and retinoidx receptor selective agonists
|
|
US5814647A
(en)
|
1997-03-04 |
1998-09-29 |
Board Of Regents, The University Of Texas System |
Use of troglitazone and related compounds for the treatment of the climacteric symptoms
|
|
FR2773075B1
(fr)
|
1997-12-31 |
2000-05-05 |
Cird Galderma |
Utilisation d'activateurs de ppar-gamma en dermatologie
|
|
AU1707599A
(en)
*
|
1998-03-20 |
1999-10-18 |
Warner-Lambert Company |
Retinoid-glitazone combinations
|
|
US7045519B2
(en)
|
1998-06-19 |
2006-05-16 |
Chiron Corporation |
Inhibitors of glycogen synthase kinase 3
|
|
WO2000030628A2
(en)
*
|
1998-11-20 |
2000-06-02 |
Genentech, Inc. |
Method of inhibiting angiogenesis
|
|
GB9908647D0
(en)
*
|
1999-04-15 |
1999-06-09 |
Smithkline Beecham Plc |
Novel compounds
|
|
GB9917405D0
(en)
*
|
1999-07-23 |
1999-09-22 |
Univ Dundee |
Methods of treatment and drug screening methods
|
|
US6723506B2
(en)
|
2000-01-20 |
2004-04-20 |
Brigham And Women's Hospital |
Method of identifying PAX8-PPAR gamma-nucleic acid molecules
|
|
NO20003591L
(no)
*
|
2000-07-13 |
2002-01-14 |
Thia Medica As |
Fettsyreanaloger for behandling av kreft
|
|
WO2002013864A1
(en)
*
|
2000-08-16 |
2002-02-21 |
Sankyo Company, Limited |
Medicinal compositions for preventing and treating cancer
|
|
EP1365796A2
(en)
|
2000-09-01 |
2003-12-03 |
Van Andel Institute |
Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
|
|
JP2004525168A
(ja)
*
|
2001-04-06 |
2004-08-19 |
エフ．ホフマン−ラ ロシュ アーゲー |
腫瘍の成長を抑制もしくは減少するための単独または他の治療薬との組合わせでのチアゾリジンジオン
|
|
US6756399B2
(en)
|
2001-06-29 |
2004-06-29 |
The United States Of America As Represented By The Department Of Health And Human Services |
Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents
|
|
US20040197834A1
(en)
*
|
2001-07-20 |
2004-10-07 |
Francois Gervais |
Method to increase expression of pgd2 receptors and assays for identifying modulators of prostaglandin d2 receptors
|
|
WO2003032988A1
(fr)
*
|
2001-10-17 |
2003-04-24 |
Sankyo Company, Limited |
Composition pharmaceutique
|
|
JP5249484B2
(ja)
*
|
2001-12-11 |
2013-07-31 |
第一三共株式会社 |
医薬組成物
|
|
WO2003053440A1
(en)
*
|
2001-12-11 |
2003-07-03 |
Sankyo Company, Limited |
Medicinal composition
|
|
WO2003082865A1
(en)
*
|
2002-04-01 |
2003-10-09 |
Sankyo Company, Limited |
Medicinal antitumor composition
|
|
TW200403055A
(en)
*
|
2002-06-25 |
2004-03-01 |
Sankyo Co |
Pharmaceutical composition of a peroxisome proliferator-activated receptor (PPAR) gamma atcivetor and a diuretic
|
|
JP2004083574A
(ja)
*
|
2002-06-25 |
2004-03-18 |
Sankyo Co Ltd |
利尿剤及びペルオキシソーム増殖因子活性化受容体（ＰＰＡＲ）γ活性化剤を含有する医薬組成物
|
|
HU0301358D0
(en)
|
2003-05-14 |
2003-07-28 |
Debreceni Egyetem |
Novel use of ppargamma agonists
|
|
US8309562B2
(en)
|
2003-07-03 |
2012-11-13 |
Myrexis, Inc. |
Compounds and therapeutical use thereof
|
|
AU2004253967B2
(en)
*
|
2003-07-03 |
2010-02-18 |
Cytovia, Inc. |
4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
|
|
WO2006074147A2
(en)
|
2005-01-03 |
2006-07-13 |
Myriad Genetics, Inc. |
Nitrogen containing bicyclic compounds and therapeutical use thereof
|
|
EP1555021A1
(en)
*
|
2004-01-16 |
2005-07-20 |
National Health Research Institutes |
Combinations of a mevalonate pathway inhibitor and a PPAR-gamma agonist for treating cancer
|
|
JP4556511B2
(ja)
*
|
2004-06-25 |
2010-10-06 |
ソニー株式会社 |
１５ｄ−ＰＧＪ２、及び、１５ｄ−ＰＧＪ２を用いた方法
|
|
US8258145B2
(en)
|
2005-01-03 |
2012-09-04 |
Myrexis, Inc. |
Method of treating brain cancer
|
|
JP2006232754A
(ja)
*
|
2005-02-25 |
2006-09-07 |
Gi Biopolis:Kk |
消化管粘膜切除後の消化管潰瘍治癒促進用スプレー剤
|
|
AU2006223000B2
(en)
*
|
2005-03-14 |
2011-06-30 |
Center For Molecular Medicine And Immunology |
Methods of treating cancer using PPAR-gamma antagonists
|
|
EP1865954A4
(en)
|
2005-03-21 |
2010-12-15 |
Metabolex Inc |
METHOD FOR AVOIDING OEDEM IN THE TREATMENT OR PREVENTION OF DISEASES AFFECTING PPAR GAMMA INCLUDING CANCER
|
|
CN101316583A
(zh)
|
2005-09-30 |
2008-12-03 |
生命医药公司 |
用特异性rxr激动剂治疗癌症
|
|
JP5186217B2
(ja)
|
2005-11-28 |
2013-04-17 |
千寿製薬株式会社 |
Ｐｐａｒアゴニスト含有医薬
|
|
CA2687957C
(en)
|
2007-05-21 |
2014-11-25 |
Senju Pharmaceutical Co., Ltd. |
Pharmaceutical containing ppar.delta. agonist
|
|
WO2010070379A1
(en)
*
|
2008-12-17 |
2010-06-24 |
Centre National De La Recherche Scientifique |
Rxr-ppargamma agonist/growth factor inhibitor combination therapy for inducing apoptosis and the treatment of cancer
|
|
WO2013003729A1
(en)
|
2011-06-29 |
2013-01-03 |
The Penn State Research Foundation |
Compositions, methods and kits for treating leukemia
|
|
WO2013090616A1
(en)
|
2011-12-13 |
2013-06-20 |
Io Therapeutics, Inc. |
Autoimmune disorder treatment using rxr agonists
|
|
US10653650B2
(en)
|
2011-12-13 |
2020-05-19 |
Io Therapeutics, Inc. |
Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
|
|
JP5987175B2
(ja)
*
|
2012-07-02 |
2016-09-07 |
学校法人福岡大学 |
乳癌，胃癌及び卵巣癌等に対する制癌剤
|
|
EP2914250B1
(en)
|
2012-11-05 |
2018-04-04 |
Commissariat à l'Énergie Atomique et aux Énergies Alternatives |
Combination of an anti-cancer agent such as a tyrosinekinase inhibitor and a stat5 antagonist, preferably a thiazolidinedione, for eliminating hematologic cancer stem cells in vivo and for preventing hematologic cancer relapse
|
|
AU2015315324A1
(en)
*
|
2014-09-08 |
2017-03-09 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating cancer comprising administering a PPAR-gamma agonist
|
|
US20190365681A1
(en)
*
|
2015-10-31 |
2019-12-05 |
Io Therapeutics, Inc. |
Treatment of cancer with combinations of rxr agonists and thyroid hormones
|
|
CN116077626A
(zh)
|
2015-10-31 |
2023-05-09 |
Io治疗公司 |
使用rxr激动剂和甲状腺激素的组合治疗神经系统紊乱
|
|
US10960013B2
(en)
*
|
2016-03-04 |
2021-03-30 |
East Carolina University |
J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
|
|
US10835507B2
(en)
|
2016-03-10 |
2020-11-17 |
Io Therapeutics, Inc. |
Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones
|
|
KR102605349B1
(ko)
|
2016-03-10 |
2023-11-22 |
아이오 테라퓨틱스, 인크. |
Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료
|
|
CA3076373A1
(en)
|
2017-09-20 |
2019-03-28 |
Io Therapeutics, Inc. |
Treatment of disease with esters of selective rxr agonists
|
|
US10966950B2
(en)
|
2019-06-11 |
2021-04-06 |
Io Therapeutics, Inc. |
Use of an RXR agonist in treating HER2+ cancers
|
|
WO2022054755A1
(ja)
*
|
2020-09-08 |
2022-03-17 |
国立大学法人愛媛大学 |
蛍光色素剤及び腫瘍細胞の検出方法
|
|
AU2022408160A1
(en)
|
2021-12-07 |
2024-06-06 |
Board Of Regents, The University Of Texas System |
Use of an rxr agonist and taxanes in treating her2+ cancers
|
|
CA3242047A1
(en)
|
2021-12-07 |
2023-06-15 |
Io Therapeutics, Inc. |
Use of an rxr agonist in treating drug resistant her2+ cancers
|